[go: up one dir, main page]

HRP20050560A2 - Pyrrolopyrimidine derivatives - Google Patents

Pyrrolopyrimidine derivatives Download PDF

Info

Publication number
HRP20050560A2
HRP20050560A2 HR20050560A HRP20050560A HRP20050560A2 HR P20050560 A2 HRP20050560 A2 HR P20050560A2 HR 20050560 A HR20050560 A HR 20050560A HR P20050560 A HRP20050560 A HR P20050560A HR P20050560 A2 HRP20050560 A2 HR P20050560A2
Authority
HR
Croatia
Prior art keywords
pyrrolo
amino
pyrimidine
carbonyl
isopropyl
Prior art date
Application number
HR20050560A
Other languages
English (en)
Croatian (hr)
Inventor
Thomas Arcari Joel
Chen Jinshan
Lagreca Susan
Arnold Marx Matthew
David Wessel Matthew
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050560(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HRP20050560A2 publication Critical patent/HRP20050560A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20050560A 2002-12-19 2003-12-08 Pyrrolopyrimidine derivatives HRP20050560A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43456802P 2002-12-19 2002-12-19
PCT/IB2003/005841 WO2004056830A1 (fr) 2002-12-19 2003-12-08 Derives de pyrrolopyrimidine

Publications (1)

Publication Number Publication Date
HRP20050560A2 true HRP20050560A2 (en) 2006-02-28

Family

ID=32682064

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050560A HRP20050560A2 (en) 2002-12-19 2003-12-08 Pyrrolopyrimidine derivatives

Country Status (34)

Country Link
US (1) US7271262B2 (fr)
EP (1) EP1578751B1 (fr)
JP (1) JP4057013B2 (fr)
KR (2) KR20070087020A (fr)
CN (1) CN1726218A (fr)
AP (1) AP2005003342A0 (fr)
AR (1) AR042509A1 (fr)
AT (1) ATE512965T1 (fr)
AU (1) AU2003286317A1 (fr)
BR (1) BR0317524A (fr)
CA (1) CA2510853C (fr)
EA (1) EA200500814A1 (fr)
EC (1) ECSP055867A (fr)
ES (1) ES2364649T3 (fr)
GT (1) GT200300289A (fr)
HN (1) HN2003000416A (fr)
HR (1) HRP20050560A2 (fr)
IS (1) IS7872A (fr)
MA (1) MA27568A1 (fr)
MX (1) MXPA05006793A (fr)
NL (1) NL1025068C2 (fr)
NO (1) NO20052802L (fr)
NZ (1) NZ540456A (fr)
OA (1) OA12976A (fr)
PA (1) PA8591701A1 (fr)
PE (1) PE20040914A1 (fr)
PL (1) PL377774A1 (fr)
RS (1) RS20050469A (fr)
TN (1) TNSN05165A1 (fr)
TW (1) TW200423939A (fr)
UA (1) UA80171C2 (fr)
UY (1) UY28132A1 (fr)
WO (1) WO2004056830A1 (fr)
ZA (1) ZA200504440B (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
BRPI0416656A (pt) * 2003-11-17 2007-01-16 Pfizer Prod Inc compostos de pirrolopirimidina úteis no tratamento do cáncer
TW201134828A (en) * 2004-04-02 2011-10-16 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2005116035A1 (fr) * 2004-05-27 2005-12-08 Pfizer Products Inc. Derives pyrrolopyrimidiniques convenant au traitement du cancer
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
PL1858877T3 (pl) 2005-01-14 2014-08-29 Gilead Connecticut Inc 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
US20070287719A1 (en) * 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US7795248B2 (en) 2005-05-18 2010-09-14 Abbott Laboratories, Inc. Substituted 7,8-dihydro-1H-pyrimido[4,5-B][1,4]diazepin-4-amines are novel kinase inhibitors
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
CA2619366A1 (fr) * 2005-08-22 2007-03-01 Amgen Inc. Composes d'uree de bis-aryle pour le traitement de maladies mediees par une proteine kinase
CN101296928B (zh) * 2005-10-28 2011-01-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
PL2385053T3 (pl) * 2005-11-17 2014-05-30 Osi Pharmaceuticals Llc Związki pośrednie do wytwarzania skondensowanych bicyklicznych inhibitorów mTOR
JP5237108B2 (ja) * 2005-12-08 2013-07-17 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬としての９員ヘテロ二環式化合物
WO2007066189A2 (fr) * 2005-12-09 2007-06-14 Pfizer Products Inc. Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree
EP1979002A2 (fr) * 2005-12-19 2008-10-15 OSI Pharmaceuticals, Inc. Combinaison d'un inhibiteur de l'igfr et d'un agent anticancéreux
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
ES2545907T3 (es) * 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
WO2008076143A1 (fr) * 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combinaison d'un inhibiteur de l'igfr et d'un agent anticancéreux
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
BRPI0820342A2 (pt) * 2007-11-07 2015-05-26 Foldrx Pharmaceuticals Inc Modulação de tráfego de proteína
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
WO2009114870A2 (fr) * 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases, et procédés d’utilisation associés
WO2009114874A2 (fr) 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés
EP2283020B8 (fr) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Imidazopyrazines et imidazotriazines substituées
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
EP2313411A1 (fr) * 2008-06-10 2011-04-27 Plexxikon, Inc. Dérivés 5h-pyrrolo-[2,3-b]-pyrazine destinés à la modulation de kinases, et des indications pour ceux-ci
US8110576B2 (en) * 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
CA2729012A1 (fr) 2008-06-27 2009-12-30 Amgen Inc. Inhibition de l'ang-2 pour traiter la sclerose en plaques
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
CA2740885C (fr) * 2008-10-16 2018-04-03 The Regents Of The University Of California Inhibiteurs d'heteroarylkinase a noyau fusionne
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
CR20170089A (es) 2009-04-03 2017-07-17 Plexxikon Inc Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
EP2421837A1 (fr) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Préparation de c-pyrazine-méthylamines
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
SG10201404886PA (en) 2009-08-17 2014-10-30 Intellikine Llc Heterocyclic compounds and uses thereof
SG178092A1 (en) 2009-08-24 2012-03-29 Ascepion Pharmaceuticals Inc 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
NZ599872A (en) * 2009-11-18 2014-08-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
BR112012016376A2 (pt) 2009-12-30 2019-09-24 Arqule Inc compostos de pirrolo-aminopirimida substituída
WO2011153553A2 (fr) * 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
AU2011326071A1 (en) * 2010-11-08 2013-05-23 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
CN103517710B (zh) 2011-02-07 2017-05-31 普莱希科公司 用于激酶调节的化合物
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
WO2012129145A1 (fr) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Polythérapie du cancer du poumon non à petites cellules (nsclc)
MX2013011612A (es) 2011-04-05 2013-10-17 Pfizer Ltd Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina.
AU2012283775A1 (en) * 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2747767B8 (fr) 2011-08-26 2019-07-17 Neupharma, Inc. Entités chimiques, compositions et procédés
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CN115403531A (zh) 2011-09-14 2022-11-29 润新生物公司 作为激酶抑制剂的化学实体、组合物及方法
WO2013112950A2 (fr) 2012-01-25 2013-08-01 Neupharma, Inc. Entités chimiques particulières, compositions et procédés
JP6101290B2 (ja) * 2012-01-25 2017-03-22 バイエル ファーマ アクチエンゲゼルシャフト 置換フェニルイミダゾピラゾールおよびその使用
RU2014149136A (ru) 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EP2897618B1 (fr) 2012-09-24 2021-11-17 Neupharma, Inc. Entités chimiques particulières, compositions et procédés
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
US20150250785A1 (en) 2012-10-04 2015-09-10 Pfizer Limited Tropomyosin-Related Kinase Inhibitors
CA2885259A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associee a la tropomyosine pyrrolo[3,2-c]pyridine
CA2885253A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associee a la tropomyosine pyrrolo[2,3-d]pyrimidine
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014153509A1 (fr) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US20170305857A1 (en) 2013-12-20 2017-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015095788A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Benzoxazine carbamates de 2-acylamidométhyle et de sulfonylamidométhyle pour l'inhibition de l'activité du rorgamma et le traitement d'une maladie
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
EP3110429A4 (fr) 2014-02-27 2018-02-21 Lycera Corporation Thérapie cellulaire adoptive utilisant un agoniste du récepteur gamma orphelin associé au récepteur de l'acide rétinoïque et méthodes thérapeutiques associées
EP3131891A1 (fr) 2014-04-15 2017-02-22 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine contenant à la fois un 1h-pyrazole et un fragment pyrimidine
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
EP3209641A4 (fr) 2014-05-05 2018-06-06 Lycera Corporation Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de ror et pour le traitement de maladie
EP3140298A1 (fr) 2014-05-07 2017-03-15 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
WO2016009296A1 (fr) 2014-07-16 2016-01-21 Pfizer Inc. Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
WO2016020784A1 (fr) 2014-08-05 2016-02-11 Pfizer Inc. Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10221181B2 (en) 2014-11-14 2019-03-05 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
JP2018510135A (ja) 2015-02-11 2018-04-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JP6793401B2 (ja) * 2015-03-11 2020-12-02 国立研究開発法人理化学研究所 難治性白血病治療薬
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
EP3368535B1 (fr) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Acides benzoïques à substitution hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations
EP3368539B1 (fr) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Composés indazole substitués utilisés en tant qu'inhibiteurs de ror gamma t et utilisations associées
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
KR20240132125A (ko) * 2015-12-02 2024-09-02 아스트레아 테라퓨틱스 엘엘씨 피페리디닐 노시셉틴 수용체 화합물
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017133669A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés 5,7-diazaindole et 5,7-diazaindazole et leur utilisation pour traiter, atténuer ou prévenir la grippe
ES2775751T3 (es) 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018233526A1 (fr) * 2017-06-19 2018-12-27 上海和誉生物医药科技有限公司 Inhibiteur de csf1r, son procédé de préparation et son utilisation
TW201920184A (zh) 2017-08-17 2019-06-01 美國華盛頓大學 Cdpk1抑制劑、組合物及與其相關之方法
EP3674325A4 (fr) 2017-08-21 2021-11-03 Taiho Pharmaceutical Co., Ltd. Protéine hybride de protéine dctn1 et de protéine ret
CN119241541A (zh) 2018-05-04 2025-01-03 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
JP2021525802A (ja) 2018-06-01 2021-09-27 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ Ｐｉ３ｋに関連する疾患または障害に対する併用療法
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN112574200B (zh) 2021-02-26 2021-06-11 安润医药科技（苏州）有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
EP4323405A1 (fr) 2021-04-12 2024-02-21 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981458A (en) * 1961-12-04 1965-01-27 Wellcome Found Pyrrolo[2,3-d]pyrimidines
US4218374A (en) * 1972-10-20 1980-08-19 Fujisawa Pharmaceutical Company, Limited Penam derivatives
DE3145287A1 (de) * 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU1794697A (en) * 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
DE59710417D1 (de) * 1996-03-15 2003-08-14 Novartis Ag N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
JP2001516353A (ja) * 1997-03-19 2001-09-25 ビーエーエスエフ アクチェンゲゼルシャフト ピロロ［２，３ｄ］ピリミジンおよびチロシンキナーゼ阻害剤としてのこれらの使用
AU752474B2 (en) * 1998-09-18 2002-09-19 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidines as kinase inhibitors
PL346700A1 (en) 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
WO2001072751A1 (fr) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
WO2002000651A2 (fr) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese

Also Published As

Publication number Publication date
EP1578751A1 (fr) 2005-09-28
MA27568A1 (fr) 2005-10-03
ZA200504440B (en) 2006-07-26
US20050037999A1 (en) 2005-02-17
EP1578751B1 (fr) 2011-06-15
AP2005003342A0 (en) 2005-06-30
UA80171C2 (en) 2007-08-27
AR042509A1 (es) 2005-06-22
CA2510853A1 (fr) 2004-07-08
TNSN05165A1 (fr) 2007-05-14
BR0317524A (pt) 2005-11-16
ATE512965T1 (de) 2011-07-15
UY28132A1 (es) 2004-07-30
NZ540456A (en) 2007-11-30
HN2003000416A (es) 2006-07-25
KR20050084402A (ko) 2005-08-26
WO2004056830A1 (fr) 2004-07-08
KR20070087020A (ko) 2007-08-27
PE20040914A1 (es) 2005-01-08
OA12976A (en) 2006-10-13
ECSP055867A (es) 2005-09-20
JP4057013B2 (ja) 2008-03-05
NL1025068C2 (nl) 2004-11-16
PA8591701A1 (es) 2005-05-24
CA2510853C (fr) 2009-04-28
US7271262B2 (en) 2007-09-18
IS7872A (is) 2005-05-30
GT200300289A (es) 2004-09-21
NO20052802D0 (no) 2005-06-09
AU2003286317A1 (en) 2004-07-14
TW200423939A (en) 2004-11-16
MXPA05006793A (es) 2005-09-08
CN1726218A (zh) 2006-01-25
EA200500814A1 (ru) 2006-02-24
PL377774A1 (pl) 2006-02-20
NL1025068A1 (nl) 2004-06-22
RS20050469A (en) 2007-11-15
NO20052802L (no) 2005-07-19
ES2364649T3 (es) 2011-09-08
JP2006512356A (ja) 2006-04-13

Similar Documents

Publication Publication Date Title
HRP20050560A2 (en) Pyrrolopyrimidine derivatives
US7435739B2 (en) Substituted pyrrolopyrimidines useful in the treatment of cancer
JP4842929B2 (ja) 癌治療に有用なピロロピリミジン誘導体
EP1287001B1 (fr) Derives de thiophene utilises comme agents anticancereux
ES2393410T3 (es) Pirrolotriazinas inhibidoras de quinasas
CN104311563B (zh) Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法
JP7128331B2 (ja) Ｐｋｍ２調節因子およびそれらの使用方法
JP2009536636A (ja) 抗癌剤として有用なトリアゾロピラジン誘導体
HRP20050191A9 (hr) Novi derivati benzoimidazola korisni kao antiproliferativna sredstva
WO2004085439A1 (fr) 4-amino[1,2,4]triazolo[4,3-a]quinoxalines substitutees
JP4511352B2 (ja) 抗癌薬として有用なイソチアゾール誘導体
JP2002322178A (ja) 二環式環基置換された４−アミノ−ピリドピリミジン誘導体

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071024

Year of fee payment: 5

OBST Application withdrawn